Navigation Links
PharmaVentures' Client Sanofi Wins Scrip 'Outsourcing Deal of the Year Award'
Date:1/12/2012

OXFORD, English, January 12, 2012 /PRNewswire/ --

PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi - Covance deal which won Scrip's 'Outsourcing Deal of the Year 2011'.

The judges described the deal as 'impressive' as it was "one the largest and most comprehensive R&D alliances in the history of the pharmaceutical and CRO industry".Under the terms of the agreement, Sanofi retains access to some of the capabilities that were divested to Covance as part of a long-term strategic alliance. Covance will provide Sanofi with an up to 10-year sole source relationship for central lab services.

Kevin Bottomley, Head of Transactions at PharmaVentures who was lead advisor to Sanofi on the deal said:  "This is a great recognition for Sanofi as this was a ground-breaking deal which ultimately supports both its overall strategic intent."

Fintan Walton, Chief Executive of PharmaVentures said: "Deal making has become both more complex and more sophisticated. This Scrip Award recognises how PharmaVentures' clients are reaching new heights in deal making. We are delighted to be advisors to this award winning deal."

Over the years PharmaVentures has built considerable experience in the M&A field including divestments of manufacturing and R&D businesses.

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals®(http://www.pharmadeals.net), containing over 42,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions.

Our Services Cover:

  • Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
  • Licensing (In and Out licensing)
  • M&A (Companies & Assets)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:
Kevin Bottomley
Head of Transactions
+44 1865-332700
Kevin.Bottomley@pharmaventures.com



'/>"/>
SOURCE PharmaVentures Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Appoints Andy Smith as Head of Corporate Finance
2. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
3. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
4. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
5. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
6. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
7. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
8. AquaStar Holdings, Inc.s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology
9. Paul Pospisil Joins Korn/Ferry as Senior Client Partner in Biotechnology and Life Sciences Practice
10. Sermo Announces New Client Center with Advanced Mining and Monitoring of Organic Physician Dialog
11. bj-diagnostik Renforce le Conseil-client Pour les Tests ADN de Fratrie et de Paternit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):